Basal or bolus dose, which is the key factor in CSII?

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) management often involves insulin therapy.
• Continuous subcutaneous insulin infusion (CSII) offers a flexible approach to insulin delivery.
• Accurate basal insulin dosing is crucial for glycemic control in T2DM patients on CSII.

Purpose of the Study:

• To evaluate the utility of glycated hemoglobin A1c (HbA1c) levels in predicting the required total daily basal insulin dose for patients with T2DM undergoing CSII.
• To establish a correlation between HbA1c and basal insulin dosage in this patient cohort.

Main Methods:

• A cohort of 268 T2DM patients using CSII was studied.
• Five-point capillary blood glucose monitoring was performed pre- and post-CSII initiation.
• The total daily insulin dose, encompassing basal and bolus components, was determined by the dose required to stabilize blood glucose levels.
• Statistical analysis was conducted to assess the correlation between HbA1c levels and total daily insulin dose, as well as 5-point capillary blood glucose measurements.

Main Results:

• A significant correlation was identified between HbA1c levels and the basal total daily insulin dose when HbA1c exceeded 9.3% (r=0.635, P<0.05).
• The average of 5-point capillary blood glucose measurements showed the strongest correlation with HbA1c.
• Fasting blood glucose demonstrated the next strongest correlation with HbA1c.

Conclusions:

• HbA1c level serves as a reliable predictor for the basal total daily insulin dose required in patients with T2DM managed with CSII.
• This predictive value can assist clinicians in tailoring insulin regimens for improved glycemic management.